A Study of the Safety and Efficacy of TRTL-913 in Healthy Volunteers (Part A) and in Adults With Tinnitus (Part B)
A legfontosabb adatok
- Ki végzi
- Tortugas Neuroscience, Inc.
- Hol
- Ausztrália és Új-Zéland10 helyszín, 2 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 100 fő, tervezett
- Kezdés
- 2026. okt. 14.
- Várható befejezés
- 2027. aug.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- TRTL-913
- Placebo
- A regiszteradat frissítve
- 2026. november 4.
Ki vehet részt
- Életkor
- 18 év – 80 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 39 feltétel megnézéseKevesebb
Ki vehet részt
- Part A Inclusion Criteria:
- Healthy male or female adults aged 18 to 64 years (or 65 to 80 years for an elderly cohort, if enrolled), as determined by the investigator
- Able and willing to provide written informed consent and comply with all study procedures
- Body mass index (BMI) 18.0 to 35.0 kilograms per square meter (kg/m\^2) and body weight greater than (>) 50 kilogram (kg)
- Clinically acceptable medical history, physical examination, vital signs, clinical laboratory tests, and 12-lead ECG, as determined by the investigator
- QT interval corrected using the Fridericia method (QTcF) of less than or equal to (≤) 450 millisecond (msec) for males or ≤470 msec for females
- Nonsmokers or light smokers (<10 cigarettes/week or equivalent vaping) for at least 3 months before dosing and willing to abstain during confinement
- Women of childbearing potential must have a negative pregnancy test and agree to use highly effective contraception throughout the required study period
- Male participants must agree to use appropriate contraception and refrain from sperm donation for the required study period; Part B Inclusion Criteria:
- Male or female adults aged 18 to 64 years
- Able and willing to provide written informed consent and comply with study procedures
- Diagnosis of subjective, stable, chronic, non-pulsatile tinnitus
- Generally healthy aside from tinnitus, with no clinically significant abnormalities on medical history, physical or neurologic examination, vital signs, laboratory tests, or ECG that would interfere with study participation
- BMI 18.0 to 35.0 kg/m\^2 and body weight >50 kg
- Willing to discontinue prohibited medications and substances before study treatment and throughout study participation
- Women of childbearing potential must have a negative pregnancy test and agree to use highly effective contraception throughout the required study period
- Male participants must agree to use appropriate contraception and refrain from sperm donation for the required study period
Ki nem vehet részt
- Use of prohibited medications, including moderate or strong cytochrome (CY)P450 inhibitors or inducers, or other prohibited foods or supplements before dosing
- Use of prohibited medications, including moderate or strong CYP450 inhibitors or inducers, or other prohibited foods or supplements before dosing
- Any clinically significant acute or chronic medical condition that, in the investigator's opinion, could affect participant safety or study assessments
- History of seizures, epilepsy, significant head injury associated with loss of consciousness, or other conditions or medications that increase seizure risk
- Active infection or clinically significant recent illness before screening or dosing
- Positive test for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
- History of malignancy within the past 10 years (except adequately treated nonmelanoma skin cancer or cervical carcinoma in situ)
- Current or recent substance or alcohol use disorder or positive drug or alcohol screening
- Current or history of clinically significant psychiatric illness or suicidal ideation or behavior that would increase study risk
- History of seizures, epilepsy, significant head injury associated with loss of consciousness, or other conditions or medications that increase seizure risk
- Clinically significant acute or chronic medical condition that, in the investigator's opinion, could affect participant safety or study assessments
- Positive test for HIV, hepatitis B, or hepatitis C
- History of malignancy within the past 10 years (except adequately treated nonmelanoma skin cancer or cervical carcinoma in situ)
- Current or recent substance or alcohol use disorder or positive drug or alcohol screening
- Current or history of clinically significant psychiatric illness or suicidal ideation or behavior that would increase study risk
- Clinically significant cardiovascular disease, clinically significant ECG abnormalities, long QT syndrome, torsade de pointes, or a family history of long QT syndrome or sudden cardiac death
- Clinically significant hepatic or renal impairment or clinically significant laboratory abnormalities
- Part A Exclusion Criteria:
- Pregnant, breastfeeding, or planning pregnancy during the study; Part B Exclusion Criteria:
- Current use of, or plans to initiate, pharmacologic or non-pharmacologic treatment for tinnitus during the study
- Regular night-shift work that could interfere with study assessments
- Pregnant, breastfeeding, or planning pregnancy during the study
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 80 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Új-Zéland.
2 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study will consist of two parts. Double blind Part A will assess the safety, tolerability, and pharmacokinetics of 7 days of dosing in healthy adults, while open label Part B will evaluate the safety, tolerability, and efficacy of a 2-week treatment course in adults with tinnitus.
A vizsgálat 3 csoportja
- Part A: Multiple Ascending Doses of TRTL-913A vizsgált kezelés
Participants will receive TRTL-913 immediate-release capsules administered once daily (QD) on Day 1 through Day 7.
Kezelés: TRTL-913
- Part A: PlaceboPlacebo, összehasonlításként
Participants will receive TRTL-913 matching placebo administered QD on Day 1 through Day 7.
Kezelés: Placebo
- Part B: TRTL-913A vizsgált kezelés
Participants will self-administer TRTL-913 immediate-release capsules QD on Day 1 through Day 14. Additional doses will be based on the results from Part A.
Kezelés: TRTL-913
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 2a, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TRTL-913 in Healthy Adult Volunteers Under Fed Conditions (Part A), and an Open-Label Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy in Adults With Tinnitus (Part B)
- Kérdések a feltételekről
- Forrás: NCT07777549: ki vehet részt
- A regiszteradat frissítve
- 2026. november 4.